Marika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma ...

Regarding market potential, I see it following an exponential curve, with forecasts indicating that by 2030, gene therapies and genetic corrections will become more widely available, potentially ...

The acquisition of Armorgenix strengthens Buscar's diversified portfolio, bridging its expertise in natural resources through Eon Discovery Inc. and sustainable materials via Terramer Inc. with ...

CC Pharma’s selection as a TOP 100 Innovator reflects its disciplined innovation strategy, strong regional footprint, and commitment to operational excellence in a highly regulated market. The award ...

Pablo Gerardo Legorreta, CEO, highlighted "a successful quarter of execution" with "20% growth in Portfolio Receipts, our top line to $727 million, an 11% growth in Royalty Receipts to $672 million." ...

SINGAPORE - Media OutReach Newswire - 9 February 2026 - Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, ...

On a day when AbbVie revealed booming sales of Skyrizi and Rinvoq and another positive adjustment to its 2025 guidance, the company also is reportedly angling to bolster its long-term prospects by way ...

MENLO PARK, Calif. and PARSIPPANY, N.J., Nov. 20, 2025 /PRNewswire/ -- Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, and TAPI – Technology and API ...

Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International that markets, distributes, and sells generic medicines in the U.S., announced a strategic collaboration with Medichem ...

In this article, we will be taking a look at the 12 Cheap Healthcare Stocks to Buy Now. Royalty Pharma plc is one of them. Royalty Pharma plc (NASDAQ:RPRX), a biopharmaceutical company specializing in ...

Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in ...

Big Pharma faces uncertainty as the Trump administration pushes MFN drug pricing and 100% tariffs on non-US manufactured patented medicines. Last night's policy announcement around a proposed 100% ...